<SEC-DOCUMENT>0001144204-12-027832.txt : 20120511
<SEC-HEADER>0001144204-12-027832.hdr.sgml : 20120511
<ACCEPTANCE-DATETIME>20120511095331
ACCESSION NUMBER:		0001144204-12-027832
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120510
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120511
DATE AS OF CHANGE:		20120511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		12832455

	BUSINESS ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE,
		STREET 2:		SUITE 200
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE,
		STREET 2:		SUITE 200
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v312847_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):&nbsp;&nbsp;<B>May
10, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center"><B>Nevada</B></TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center"><B>1-12584</B></TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center"><B>13-3808303</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center">(State or other jurisdiction of incorporation)</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">(Commission File No.)</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">(IRS Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3985 Research Park Drive, Suite 200,
Ann Arbor, Michigan 48108</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)&nbsp;&nbsp;(Zip
Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code:&nbsp;<B>(734) 332-7800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Item 5.02 &nbsp;&nbsp;&nbsp;&nbsp;Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">To improve corporate
governance and strengthen the Board, on May 10, 2012, the Board of Directors of Synthetic Biologics, Inc. (the &ldquo;Company&rdquo;)
determined to split the roles of Chairman and Chief Executive Officer and appointed an independent,&nbsp;non-executive Chairman
of the Board of Directors. The Board of Directors has appointed Jeffrey J. Kraws to serve as the Company&rsquo;s independent,&nbsp;non-executive
Chairman. Mr. Kraws has served on the Company&rsquo;s Board of Directors since January 2006, and will continue to serve on the
Compensation and Nominations Committees. For his services as independent, non-executive Chairman of the Board, Mr. Kraws will be
issued options exercisable for 100,000 shares of the Company&rsquo;s common stock and will receive annual compensation of $150,000.
Jeffrey Riley will continue to serve as the Company&rsquo;s Chief Executive Officer and President, and as a member of the Company&rsquo;s
Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and
Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Exhibits.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0">Exhibit 99.1 Press Release dated May 11,
2012&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD STYLE="width: 19%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 81%; padding-right: 0.8pt">SYNTHETIC BIOLOGICS, INC.</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="padding-right: 0.8pt">Date: May 11, 2012</TD>
    <TD STYLE="padding-right: 0.8pt">By: <U>&nbsp;&nbsp;/s/ Jeffrey Riley&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Name:&nbsp;&nbsp;&nbsp;Jeffrey Riley</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer and President</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 17%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.2pt 0pt 0; text-align: center"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.2pt 0pt 0; text-align: center"><B>Number</B></P></TD>
    <TD STYLE="width: 83%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.2pt 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.2pt 0pt 0"><B>Description</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center">99.1</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">Press Release dated May 11, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v312847_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Synthetic Biologics Appoints Jeffrey
J. Kraws as Independent Chairman</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ann Arbor, MI, May 11, 2012 &ndash;
</B>Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying
medicines for serious illnesses, announced today that to improve its corporate governance and strengthen the Board, it has split
the roles of Chairman and Chief Executive Officer, and appointed Jeffrey J. Kraws to serve as its independent, non-executive Chairman
of the Board. Mr. Kraws has served on the Company&rsquo;s Board of Directors since January 2006, and will continue to serve on
the Compensation and Nominations Committees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Kraws is Chief Executive Officer and
co-founder of Crystal Research Associates. Well known and respected on Wall Street, Mr. Kraws has received some of the most prestigious
awards in the industry. Among other awards, he was given a &ldquo;5-Star Rating&rdquo; in 2001 by Zacks and was ranked the number
one analyst among all pharmaceutical analysts for stock performance in 2001 by Starmine.com. Prior to founding Crystal Research
Associates in 2003, Mr. Kraws served as co-president of The Investor Relations Group, a firm representing primarily under-followed,
small-capitalization companies. Previously, Mr. Kraws served as a managing director of healthcare research for Ryan Beck &amp;
Co. and as director of research/senior pharmaceutical analyst and managing director at Gruntal &amp; Co., LLC (prior to its merger
with Ryan Beck &amp; Co.). Mr. Kraws served as managing director of the healthcare research group and senior pharmaceutical analyst
at First Union Securities (formerly EVEREN Securities); as senior U.S. pharmaceutical analyst for the Swedish-Swiss conglomerate
Asea Brown Boveri; and as managing director and president of the Brokerage/Investment Banking operation of ABB Aros Securities,
Inc. He also served as senior pharmaceutical analyst at Nationsbanc Montgomery Securities, BT Alex Brown &amp; Sons, and Buckingham
Research. Mr. Kraws also has industry experience, having been responsible for competitive analysis within the treasury group at
Bristol-Myers-Squibb Company. He holds an MBA from Cornell University and a BS degree from State University of New York-Buffalo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We congratulate Jeff on his appointment
as independent Chairman of the Synthetic Biologics&rsquo; Board. This important step strengthens Synthetic Biologics&rsquo; corporate
governance practices,&rdquo; stated Jeffrey Riley, Chief Executive Officer, President and Director of the Board at Synthetic Biologics.
&ldquo;Jeff&rsquo;s life science experience will be instrumental in guiding our business and strategic development initiatives.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon his appointment Mr. Kraws stated,
&ldquo;I look forward to working closely with Jeff as the Company continues to build its pipeline of synthetic DNA-based therapeutics
and innovative medicines for serious illnesses. Transitioning the Chairman role to an independent board member should allow our
CEO and his management team to focus on the operations of the Company, with the ultimate objective of increasing value for our
shareholders.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics is a biotechnology
company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses.
Synthetic Biologics is developing, or has partnered the development of, product candidates for the treatment of pulmonary arterial
hypertension (PAH), relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, fibromyalgia and amyotrophic lateral
sclerosis (ALS). For more information, please visit Synthetic Biologics&rsquo; website at www.syntheticbiologics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><I>This
release includes forward-looking statements on Synthetic Biologics&rsquo; current expectations and projections about future events.
In some cases forward-looking statements can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot;
&quot;continue,&quot; &quot;expects,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot;
&quot;estimates,&quot; and similar expressions. </I></FONT><I>These statements are based upon current beliefs, expectations and
assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements
regarding the effects of appointing an independent, non-executive Chairman. The forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements.
Important factors that could cause actual results to differ materially from those reflected in <FONT STYLE="color: windowtext">Synthetic
Biologics&rsquo;</FONT> forward-looking statements include, among others, a failure to maintain and attract independent board members,
a failure by us to achieve desired results from our clinical development programs, a failure by us to successfully commercialize
our product candidates, a failure to increase shareholder value and other factors described in <FONT STYLE="color: windowtext">Synthetic
Biologics&rsquo; </FONT>report on Form 10-K for the year ended December 31, 2011 and any other filings with the SEC.<FONT STYLE="color: windowtext">
The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation
to update any forward-looking statements contained in this release on account of new information, future events, or otherwise,
except as required by law.</FONT></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Kris Maly</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vice President of Corporate Communication</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(734) 332-7800, ext. 22</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">###</P>



<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!!`48#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBL;4]=
M6U<P6ZB24<,3T7_$T`;-&:YB)-7U$[FG=%/H=H_2I+SPW<7A23^T9HY$7:JH
MQVCU]^:SK2E"-X1YGV+IQC*5I.R.CHKEUT/7;4`VVLLV/X9.1^M/;5M:TNV:
M34+$7*JX&Z#@XYR?3L/SK&EB)3FH2@TW]WWFTL.K7A-/\_Q.EHK,TO7]/U;Y
M;>?$HZPR#:X_#_"M.NMIK1G.TT[,****0@HHKS[XE^/)_"T4.GZ:$_M&Y0OY
MCC(A3.,X[DG./I0!Z#17SI8:+X]\7P'489[Z>%B=LLUWY:M@_P`(R/T&*C7Q
M#XU\#:HMO=W-TCK\WV>[?S8Y%]B2>/<&@#Z/HKQ_Q?K&KZQX3L?&'A_4KZT@
MV^5>VL4Q`C(.-W'H>#[$&IOA3XYN;Z[ET/6+N2>=\R6LTS99O[R$_J/QH`]:
MHKGO&GB:+PKX<GOR5:X;]W;1G^*0]/P'4_2O(/!%YXL\6>)(K5M?U(6L9\VZ
M=9R,)GH/0D\#\?2@#Z`HKYR\5^*O$-KXNUBVM];OXH(KN1(XTF("@'@"O7OA
MYXM7Q5X?4SN/[1M<1W*_WO1_H?YYH`Z^BO/_`(NZG?Z5X8M)]/O)[65KQ4+P
MN5)&QCCZ<"N%TK5O%NK>`;R2POM4N[^/5(UW1.6D6/RFR/IG%`'O5%?.%U=?
M$:RMI+FZGU^&",9>21F"J/<U3L?$7C34[C[/8:MJ]S-M+>7%*S-@=3B@#Z;H
MKP[PI_PL#_A+-+_M(ZY]B\\>=Y^[9MP?O>U8&F^+/$4GBVU@?7+]H6OU0H9C
M@KYF,8],4`?2%%%>2?&'7-6TG4=*33M2NK19(9"XAD*AB",9H`];HKQ3_A(=
M9_X4N=1_M6[^W?VCY?VCS3OV[NF?2N2T_7/'&K.Z:=J6LW;1@%Q#(S%0>F:`
M/IBBOG;_`(N=Z^(O_'ZU--_X6%_8^M_:#KOG^1%]FW[MV[S5W;??;G/M0![K
M17SG--\2;>&2::3Q!'%&I9W8L`H'))K-L_$WC'4+I+:SUC5;B=\[8XYF+-@9
M.!]*`/IZBO`--_X61_:ME]H/B#R/M$?F;]VW;N&<^V*K>.?%7B"R\9ZS;VNM
M7T,$4Q"1QS$*HVCH*`/HBBN?U'Q':^'?"$.K:@[.!!'A0?FE<J,*/<_XUXEJ
M'C7Q?XPU+[-92W*!R?+L[#*X'N1R?J3B@#Z-HKYMN]*\=^'(?[0G_M6VC'S-
M,EP7"_[V"<?C7>?#KXEW.JWT>BZXRM<2#%O=`!=Y`^ZPZ9]#WH`]6HHHH`KW
MTQM[&>5?O*A(^M<II=O]HN@6Y.0,GU/>NLO83<64T(ZNA`^M<KI4OE2L#]Y6
M#8^G6F@.O1%C0(HPHZ"G4BL'4,IR",BEI`%&***`,/5O"]EJ7[U%^SW(Y66/
M@@_A67:Z]?:%=K8:^"\)XCO`/_0O7ZUV%4-6TR+5;%[>0+D_=9ESBK4NDMC6
M-2_NSU7Y%Y65T5U8,K#((.012UP_AR[N](U.XTJZN(FT^W_Y:,W^J8D`+GMD
ML.#^%=Q4R5G8FI!P=@KQ/XTZ)=KJ]KK:1L]F\(AD<#(C8$D9]`0?TKVRN%\0
M?$[P]HVIW>D:A:7LLD.%D"PJR,"`>[<C!]*1!P/A'XL2^'])M]+O=.%S;0+M
MCEA?:X7/<'@_I7477B;X>>/)K5-6:2&>+(B%R6BQNQD;E..PZFM>Y^&WA#7[
M2*]M[)K47""57M7*9##(^7E?TKS/Q[\.6\(VT5];WIN;*601$2*`Z,02.G!'
M!]*`/;=)\-:/I.BRZ78VX^P3[F>-G+AMPP>2>A%?/?B?0[SP/XM,4$CIY3B>
MRG]5SQ^(Z'_Z]>G?!;5KJ\T*^T^=V>.RE7R2QSM5@3M^@(/YU>^,&FVUUX+>
M^D3_`$BSE0Q..HW,%8?0Y_04`>2^+_%M[XTU.U=H61(HUCBMT.<N<;B/<GI[
M`5[CX"\*)X4\.QP2*#?3XENG'][LOT4<?GZUY1\']*MM1\823W*[S90>=$IZ
M;\A03],\5]`4`?+_`(LC$WQ`U:(G`DU%D)],MBKNGWFH?#7QVZS!BL#^7.@Z
M3PD\$?A@CW%5/$W_`"4;4O\`L*'_`-#%>N?%3PA_;NC?VI9QYU"Q4G"CF6+J
M5^HZC\?6@"A\8;N"_P#`NF7=M(LD$UVCQNO1@8WQ3/@?_P`@35O^OI?_`$`5
MY8WB&>;P>OA^;+Q178N('S]P;6#+],G(_&O4_@?_`,@35O\`KZ7_`-`%`'6_
M$7_DGVM?]</ZBO)?@[_R/?\`VZ2?S6O6OB+_`,D^UK_KA_45Y+\'?^1[_P"W
M23^:T`?0-?*$%TMCXE2\=2R07OFLJ]2%?.!^5?5]?*5I;QWGBF&UF!,4U\(W
M`."5,F#S^-`'KG_"[](_Z!-]^:?XUP7Q!\96OC&[L9K6UFMQ;QNC"4CG)!XQ
M]*]5_P"%1^$?^?.X_P#`E_\`&O-?BAX6TKPM?:=%I43QI/$[2;Y"^2",=?K0
M!,/^2"G_`+"?_LU4OAQXOT_PC?7\VH1W#K<1HB>2@8Y!)YR1ZU='_)!3_P!A
M/_V:H/AAX6TKQ3?ZC#JL3R)!$C)LD*8))ST^E`'??\+I\-?\^VI?]^5_^*KI
M_"WBW3_%UK<7&GQW")!((V\Y0ISC/&":Q?\`A4?A'_GSN/\`P)?_`!KH/#WA
M?2_"]M-!I<3QQS/O</(7R<8[T`/\4?\`(I:S_P!>,W_H!KP3X6?\E$TKZ2_^
MBVKWOQ1_R*6L_P#7C-_Z`:\#^%G_`"432OI+_P"BVH`^DJ^8/B'_`,CWKW_7
M<_\`H(KZ?KY@^(?_`"/>O?\`7<_^@B@#J/BSJ,CCP_I@;]U%8K.5]688'Z`_
MG7:?!_18++PD-3\L?:;YV9GQSL4X5?IP3^-<1\6+"2.30-0VGRIK!8=W^TO.
M/R;]*[KX0:O#?>#4L`X^T6+LCIGG:264_3DC\*`.^=%D1D=0R,,,I&01Z&O.
M8?@[I5KJT=_;:G>PM%.)HT4+A,-D`<=.U>CLRHI9B`H&22<`"O(#\8]0N->^
MP6&DVTT4EUY,#F1LNI;`./?K0![!1110`5A:I$-)BO=2BVY9``I&<,6&:W:@
MN[."^@\FYC$D9()4G@D5%12<&H[B=[:&%8>(E\I=\(,9Z&/C'X5T2,'16`(R
M,X-<5JOA^ZTJ1[K3E:>T/+P=63Z>HJ/2O$CP*!&WFQ#K$QY7Z>E>52Q57#SY
M,1MW,U.VDCNZ*S+/7K"[P!,(I/[DG%:0((R#D>HKU85(S5XNYHFGL+115*YU
M?3[03^?=Q(8,>8">1D9''>M$F]A2G&*O)V/(_BY#&NN0W%I/M>>#R[@1OC)1
MN-P'U'7T%>E^#=6?6_"6GWLK;IC'LE/JZ\$_CC/XUYGXG1?&%Y-?Z9`D5Q&^
MR6.214+Q?PRG<0!T(/X5WOP]TV^TGPREI=QP[=YEBDAF$@=6Y[<?J:P]G4IU
MI1FK'MUL1A<3E=*=*:<E]_7_`(!UM>8?$SX=W6NW0UK1U5[P($GMR<&4#HRD
M\9QQCOQ7I]9U_KVDZ7.(+_4;>WE*[PDC@';TS].#6QXQX'IOBSQKX0A&G*EQ
M'#'PL%W:E@GL#C('MG%,O;CQM\0+F&*:VNKE4;Y$6'RHD)[DG`_$FOHNWN(+
MRW2>WECF@D&Y)$8,K#V(J6@#EO`7A(>$=!^S2R+)>3OYMPZ]-V,!1[`?UJ'X
MG6MQ>^`[V"U@EGF9X\1Q(68_..PKKB0`2>`*9;W$-W;QW%O*LL,BAD=#D,#W
M!H`\<^#NDZEI_B/4)+W3[JV1K0*K30L@)WC@$BO9Z*,XH`^<O$6@ZS-X_P!0
MGBTF^>%M1+K(MNQ4KO'(..E?1M9EIXBT:_O39VFIVLUP,_NTD!)QUQZX]JTZ
M`/`?B'X!O-,\0M<Z/83W%C>9D5((R_DO_$N!T'<?EVKL_@UI][I^CZHE[9SV
MS/<J56:,H2-@Y&:]+J*6Z@@FAAEF1))V*Q*QP7(&2!Z\#-`&#X^MYKKP+J\%
MO$\TSP86.-2S,<CH!7E_PGT;5+'QKYUYIMW;Q?99!OEA95SE>,D5[G10`5\T
MZ;X>UI/%]I*^D7ZQ#4%8N;=L`>9G.<=*^EJS$\1Z++J/]GIJEJUWNV>4)1DM
M_=^OMUH`TZ\@^,NEZCJ.I:2UE87-RJ0R!C#$SA3D=<5Z_10!X?\`V/JG_"DC
M9?V==_:O[1W^1Y+;]N[KMQG%<EI=KXQT221],LM7M'E`#F*W8;@.F>*^F9YX
M;6!Y[B5(H8QN=W8*JCU)-5-.US2]7+C3[^"Y:/!=8WR0#T./2@#P3^U_B3_S
MTU[_`+\-_P#$UV/PUO\`Q?<^)I4UY]3-I]F8K]JB*KOW+CD@<XS7K-%`&7XD
MC>;POJT42,\CV<RJBC)8E#@`5XC\-=#U>S\>Z9/=:7>P0J)-TDD#*H_=L.21
M7OOVF`W1M?-3SP@D,>?FVYQG'ID5+0`5\X^/-`UFZ\:ZW-;Z3?2Q/,2CQV[,
MK#:.A`YKZ.K/U'7=*TAT34-0M[9W&561P"1ZX]/>@#,U3PS:^)O!\&EWH:-O
M)C*.!\T4@48/]"/K7B-YX:\7^!M4-S;Q72%.%N[,%T=??'\F%?1T4L4\*30R
M))$X#*Z'(8>H(ZT^@#YMO?%OC;Q';G3I)KR:.3Y6BM[;:7]CM&:[CX;?#:ZT
MZ^CUS7(A%-%S;6I.2I_OMZ'T%>L\*">`.I-9UCX@T?4KIK:RU*VN)U!)2.0$
MX'4CU'TH`TJ***`"BBB@`K#U;PKI^J,9@K6US_SVAX)/N.AK<II;%1.G&:M)
M7$TGHSSN]\-Z]89*1QZA".\9VO\`D:R&UF[TUMLBWUFP[,K`5ZM)<K$,MG\%
M)JD^L6;-Y3K*V>Q@8C^5<4LNA>\&T82PZ>SL>>V'C,'4;<7FL3I;!P9#R>!V
MX%5M4AO=0GNM1M8X[V-W+&6V<2!1VR!R./45Z:EMIL^&^PP$^K0`?TJY###`
M"(88XP?[B@?RKT,!*IA&W?FOW./%9:L3!0G)Z:GD?ASX?/XAN(]2U1U%ANSY
M8;+RX/0_W1^M>P1QI%&L<:A$0!551@`#H!0J*N=J@9.3@=33JWKXB5:5Y'5A
M,+##0Y(A7!ZW<-;_`!#DV:GIU@6TJ,;KY0P;]Z_`RRUWE03V5I<L&N+6&5@,
M`R1AB!^-8'4<[\/V!\,LB[&V7<X,T7^KG/F$ET'922<#MBNIIJ(L:*B*%51@
M*HP`*=0`R;_42?[I_E6)X)P?!&BXZ?8X_P"5;Q&::B+&@1%5548"J,`"@!U8
MGC"*[F\(:K'9!S.UNP41_>([@>Y&:VZ*`.#UN^T.]\/:3;:)+;279N+<Z?';
MD;XR&4DX'*@*&W9]P:[RJ\6GV<%P]Q#:01SO]^1(P&;ZD#)JQ0`5ROBFYM[3
MQ#X8FN9XH8ENILR2N%4?N6[FNJJ*>V@N5"SP1RJ#D"1`P'YT`,M+ZTOXS)9W
M4%P@.TM#('`/ID58J*"V@MD*00QQ*3DB-0H)_"I:`*>K)<R:-?)9DBZ:WD$)
M']_:=OZXKA+N\T*3X7PV%FT!O#`D5O;(1YZW7&/E^\'#\D_4UZ/5<6%FMV;M
M;2`7)ZS",;S_`,"ZT`2PAQ#&)#EPHW'WQS3Z**`.7\;;%L],ENUW:;%J$3WN
M1E1&,X+?[(?835%=6@E^(6GPHVE7+2Q3+%-:LQEBB"AL.0=IR1T]LBNU90ZE
M6`*D8((R"*@M["SM!BVM((!G=B*,+SZ\4`6****`.>3'_"Q9AW_LI/\`T:U=
M#3?+3S/,VKOQC=CG'IFG4`%<?I]WI]AXN\1?VM/;P74C1O$]PP4/;>6``I/8
M-OR!WZUV%5[FQM+W9]JM8)]AROFQAMI]L]*`,_PO)82Z##)IEJ]M8L[F&-^,
MKO/S`=E/4#T(K8I``H``P!T`I:`*.M>2=#OQ<),\!MY!(L`S(5VG.WWQTKB-
M,NX[:_\`#D"WNEZU;%O*LW@3R[FW7RS\Q"D@K@8;@=17HM5H-/LK:=YH+2WB
ME?[[QQ!6;ZD#F@"S1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
,4`%%%%`!1110!__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
